8-K: Aptevo Therapeutics Implements 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Aptevo Therapeutics Inc. has announced a 1-for-20 reverse stock split of its common stock, effective May 23, 2025, aimed at increasing its per share price to meet Nasdaq listing requirements.

Summary

• Aptevo Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders on May 14, 2025, where stockholders approved alternate amendments to the Certificate of Incorporation for a reverse stock split ranging from 1-for-6 to 1-for-20.
• On May 21, 2025, the Board of Directors approved a 1-for-20 reverse stock split.
• The Company filed a Certificate of Amendment with the Delaware Secretary of State on May 23, 2025, to effect the 1-for-20 reverse stock split.
• The reverse stock split became effective at 5:01 p.m. Eastern Time on May 23, 2025.
• Every 20 shares of common stock were automatically combined into one share, without changing the par value per share.
• Proportionate adjustments will be made to outstanding stock options, restricted stock units, and warrants, including exercise prices and number of shares reserved for issuance.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the average closing sales prices for the five trading days preceding the filing date.
• The reverse stock split affects all stockholders proportionately and does not change percentage ownership, except for fractional shares.
• The common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis on May 27, 2025, under the new CUSIP number 03835L 504.

Sentiment

Score: 3

Explanation: The implementation of a reverse stock split, especially at a 1-for-20 ratio, generally indicates a distressed stock price and potential delisting risk, which is a negative signal to the market. While it addresses a technical listing requirement, it doesn't resolve underlying business challenges or improve financial performance. The mention of 'ability to continue as a going concern' in risks further dampens sentiment.

Positives

• The reverse stock split is intended to increase the per share price, which can help the company maintain its listing on The Nasdaq Capital Market.
• Maintaining Nasdaq listing provides continued access to public capital markets and liquidity for shareholders.

Negatives

• A reverse stock split often signals a low stock price, which can be perceived negatively by the market and may indicate underlying financial or operational challenges.
• While the percentage ownership remains the same, the reduction in the number of outstanding shares can sometimes lead to reduced trading liquidity.
• Cash payments for fractional shares might be a minor inconvenience for some shareholders.

Risks

• Ability to continue as a going concern.
• Deterioration in the company's business or prospects.
• Further assessment of preliminary or interim data or different results from later clinical trials.
• Adverse events and unanticipated problems and adverse developments in clinical development, including unexpected safety issues observed during a clinical trial.
• Changes in regulatory, social, macroeconomic, and political conditions.
• Risks disclosed in the Company's other SEC filings.

Future Outlook

The company anticipates its common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis on May 27, 2025. The forward-looking statements acknowledge risks that could cause actual events or results to differ materially, including the company's ability to continue as a going concern and various clinical development and macroeconomic factors.

Management Comments

• The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Industry Context

Reverse stock splits are common corporate actions in the biotechnology and pharmaceutical industries, particularly for smaller companies or those in clinical development stages, when their stock price falls below exchange minimums. This action by Aptevo Therapeutics is a strategic move to maintain its Nasdaq listing, which is crucial for access to capital markets and investor visibility, a common challenge for companies with long development cycles and no immediate product revenue.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by companies, particularly in the biotech sector, to meet stock exchange minimum bid price requirements (e.g., Nasdaq's $1.00 minimum). Companies like Sorrento Therapeutics (SRNE) and Athersys (ATHX) have also undertaken reverse stock splits in recent years for similar reasons, often following periods of significant stock price decline.
• The 1-for-20 ratio is a relatively aggressive split, indicating a significant need to boost the per-share price, which is not uncommon for companies facing potential delisting.
• The proportionate adjustment of equity awards (options, RSUs, warrants) and cash in lieu of fractional shares are standard practices in reverse stock split implementations across industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but with a proportionally higher per-share price; percentage ownership remains largely the same (except for fractional shares receiving cash). Those with fractional shares will receive cash.
• Employees (with equity awards): Stock options, restricted stock units, and warrants will be adjusted proportionately, meaning fewer shares but higher exercise prices for options/warrants, maintaining the intrinsic value of their equity.
• Investors/Market: The action aims to maintain Nasdaq listing, which is crucial for liquidity and visibility, potentially preventing delisting and allowing continued trading on a major exchange.

Next Steps

• Common stock to begin trading on The Nasdaq Capital Market on a split-adjusted basis on May 27, 2025.
• Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof.
• The Company disclaims any intent or obligation to update forward-looking statements, other than as may be required under applicable law.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, Reverse Stock Split, Nasdaq Listing, Stock Consolidation, Corporate Action, Biotechnology, SEC Filing, 8-K, Share Capital Adjustment